DrugDrug NameDrug Indication
DB04895PegaptanibFor the treatment of neovascular (wet) age-related macular degeneration.
DB04932DefibrotideIndicated for the treatment of severe hepatic veno-occlusive disease (VOD), also known as sinusoidal obstruction syndrome (SOS), with renal or pulmonary dysfunction following hematopoietic stem-cell transplantation (HSCT).[label]
DB04973LErafAONIntended for the treatment of various forms of cancer.
DB04998AGRO100Investigated for use/treatment in cancer/tumors (unspecified), kidney cancer, leukemia (myeloid), and pancreatic cancer.
DB05141LY2181308Investigated for use/treatment in cancer/tumors (unspecified) and solid tumors.
DB05165LY2275796Investigated for use/treatment in cancer/tumors (unspecified) and solid tumors.
DB05202Egaptivon pegolPlatelet aggregation, thrombosis and acute coronary syndromes
DB05406GTI-2501Investigated for use/treatment in prostate cancer and solid tumors.
DB05528MipomersenUsed in patients with homozygous familial hypercholesterolemia as an adjunct to diet and other lipid-lowering medications.
DB05530CPG 10101Investigated for use/treatment in hepatitis (viral, C) and viral infection.
DB05798GEM-231Investigated for use/treatment in solid tumors.
DB06014EteplirsenEteplirsen is indicated for treatment of certain individuals with Duchenne muscular dystrophy (DMD). Its use is limited to those with a confirmed mutation of the DMD gene which would benefit from exon 51 skipping. Based on clinical studies showing increased dystrophin production in skeletal muscle in some patients given this drug, the above indication was approved under accelerated approval. Further confirmatory trials are required to demonstrate clinical benefit of eteplirsen.
DB06094ApatorsenInvestigated for use/treatment in cancer/tumors (unspecified).
DB06184AEG35156Investigated for use/treatment in cancer/tumors (unspecified) and leukemia (myeloid).
DB06224AlicaforsenInvestigated for use/treatment in crohn's disease and ulcerative colitis.
DB06293PegnivacoginInvestigated for use/treatment in thrombosis, coronary artery disease, and vascular diseases.
DB06451AprinocarsenInvestigated for use/treatment in lung cancer.
DB06556EdifoligideInvestigated for use/treatment in cardiac surgery, peripheral vascular disease, and kidney disease.
DB06662AbetimusInvestigated for use/treatment in kidney disease and systemic lupus erythematosus.
DB06759FomivirsenIndicated for the local treatment of cytomegalovirus (CMV) retinitis in patients with acquired immunodeficiency syndrome (AIDS), when other therapy has been ineffective or is considered unsuitable [FDA Label, L1428].
DB12851MiravirsenNot Available
DB13161NusinersenIndicated for the treatment of spinal muscular atrophy (SMA) in pediatric and adult patients.
DB13688DrisapersenNot Available
DB06181IMO-2055Investigated for use/treatment in renal cell carcinoma, solid tumors, and lung cancer.
DB05463ISS-1018Investigated for use/treatment in colorectal cancer, hepatitis (viral, B), and lymphoma (non-hodgkin's). ISS 1018 is currently being investigated in combination with HBsAg vaccine as a prophylactic treatment for to prevent Hepatitis B in adults. It has also been investigated in combination with rituximab for treatment of b-cell or non-hodgkin's lymphoma.
DB05559NF-kappaB DecoyInvestigated for use/treatment in atopic dermatitis, inflammatory disorders (unspecified), and skin infections/disorders.
DB15019MongersenNot Available
DB15030GTI-2040Not Available
DB15067VolanesorsenNot Available
DB15285ARC-19499Not Available
DB15369AganirsenNot Available
DB15455CenersenNot Available